Category - Developments

Developments

Firefly, WaveDancer in merger agreement

Closely-held Firefly Neuroscience and WaveDancer (NASDAQ:WAVD) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop...

November 16, 2023

Developments

LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

November 15, 2023

Developments

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre approved the company’s planned clinical study to investigate the...

November 14, 2023

Developments

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Hepion Pharmaceuticals (NASDAQ:HEPA) presented new data from its Phase 2 ALTITUDE-NASH trial demonstrating that 17 weeks of rencofilstat treatment significantly reduced liver stiffness in subjects with advanced F3...

November 13, 2023

Developments

Elucid raises $80-million in Series C round

Closely-held Elucid raised $80-million to drive the commercialization of its AI-powered cardiovascular diagnostic tools. The round was led by Elevage Medical Technologies. Elucid’s FDA-cleared software is a non-invasive...

November 9, 2023

Developments

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Profound Medical (NASDAQ:PROF; TSX:PRN) reported that the U.S. Centers for Medicare and Medicaid Services (CMS) has expanded TULSA’s HCPCS C code, C9734, for use in the ambulatory surgical center (ASC) setting...

November 3, 2023

Developments

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

Hepion Pharmaceuticals (NASDAQ:HEPA) published a new research study in mice where rencofilstat prevented the growth of human hepatitis C virus (“HCV”)-associated liver tumors. HCV-infected mice developed small liver...

October 25, 2023

Developments

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

PharmaJet launched a study in Nigeria to evaluate the intradermal administration of a fractional inactivated poliovirus vaccine (fIPV) using the company’s Tropis ID Needle-free Injection System. Children at 22 urban and...

October 25, 2023

Developments

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Personalis (NASDAQ:PSNL) presented positive data on its NeXT Personal platform’s ability to detect and monitor residual and recurrent disease (MRD) in patients with early-stage lung cancer. NeXT Personal is a whole...

October 23, 2023

Developments

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

Anixa Biosciences (NASDAQ:ANIX) appointed Dr. Mark Goldberg as the ninth independent member of the company’s Cancer Business Advisory Board (CBAB). “Mark brings valuable clinical expertise in oncology, and his extensive...

October 23, 2023

Category - Developments

Firefly, WaveDancer in merger agreement

LENZ Therapeutics, Graphite Bio in merger accord

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Elucid raises $80-million in Series C round

Profound Medical’s TULSA gets device-intensive status; CMS extension of temporary C Code to ambulatory surgical center setting

Hepion’s rencofilstat demonstrates anti-cancer activity in hepatitis C-associated cancer model

PharmaJet launches Nigerian study of Tropis-administered poliovirus vaccine

Personalis presents positive NeXT Personal assay data in early-stage lung cancer

Anixa Biosciences appoints Dr. Mark Goldberg to Cancer Business Advisory Board

General

More